Expecting pivotal data this year, the company has raised a Series C round to support the launch of a noninvasive device designed to treat brain diseases using light and sound.

Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...

Alzheimer’s disease affects nearly 6 million Americans. It’s the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older, and the problem is only getting ...

Discover the collaboration between Ochsner Health and Cognito Therapeutics to advance brain health innovations in New Orleans ...

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...

Christian Howell, CEO of Cognito Therapeutics, sits down with Nasdaq’s Kristina Ayanian to discuss the company’s breakthrough approach to treating Alzheimer’s using light and sound stimulation. From ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...